Sociedad Americana de Hirudoterapia

Bundesamt für Sicherheit im Gesundheitswesen

BASG · Austria · europe

Regulatory jurisdiction profileJurisdictional reference
Medical device clearednational regulator

Austria's federal authority for safety in health care — applies EU MDR directly; leech-specific regulation has not been independently verified by ASH and is presumed to follow the general EU medical-device framework.

Regulatory Profile

Agency type
national regulator
Region
europe
Country
Austria
Leech status
medical device cleared
Last ASH review
2026-05-25

Relevant Regulation Codes

  • Medizinproduktegesetz 2021 (MPG 2021) — Austrian implementation of MDR
  • Regulation (EU) 2017/745 (MDR) — direct effect

Prescriber Requirements

  • Physician (Arzt) prescription required under Austrian medical practice law
  • Specific scope of non-physician practitioners (e.g., Heilmasseur) for leech therapy has not been independently verified by ASH

Supply Chain & GMP

EU MDR-aligned manufacturer / authorised representative registration via BASG / AGES Medizinmarktaufsicht; German-language labelling per Austrian consumer-protection law.

Import/Export Rules

Intra-EU free movement for CE-marked devices. Third-country imports require BASG notification plus standard CITES Appendix II paperwork for Hirudo medicinalis and live-invertebrate veterinary clearance.

Reimbursement Context

ÖGK (Österreichische Gesundheitskasse) coverage for inpatient indications via DRG bundling; specific outpatient hirudotherapy reimbursement status not independently verified by ASH.

ASH Editorial Notes

Austria's leech-specific regulation has not been independently verified by ASH; the entry reflects the default EU MDR framework expected to apply. Austrian clinical use of hirudotherapy has historic anchor points in Vienna's traditional medicine community but precise regulatory references should be confirmed before relying on this entry for compliance decisions.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.